CimaVax-EGF
Vaccine description | |
---|---|
Target | Human epidermal growth factor |
Vaccine type | protein "subunit" / conjugate |
Clinical data | |
Trade names | CimaVax-EGF; CIMAVAX[1] |
Other names | recombinant human EGF-rP64K/montanide ISA 51 vaccine |
Routes of administration | intramuscular[1] |
Legal status | |
Legal status |
|
Identifiers | |
DrugBank |
CimaVax-EGF is a
The vaccine was developed by the
Mechanism
CimaVax is an active
Research
Cuba
Early trials showed a trend towards improved survival among vaccinated test subjects.
Researchers caution that the early results to date have been in relatively small, early-stage trials with patients that were carefully selected based on predefined inclusion and exclusion criteria, and given specialized oncology care; they may therefore not be representative of most patients who might benefit from the vaccine.[10] It has been urged that CimaVax be tested in patients with earlier-stage NSCLC cancer and in patients who are not candidates for chemotherapy, and that research be conducted to determine which subgroups of NSCLC patients do and don't respond to the vaccine.[10] It has been suggested that CimaVax may also be effective in other types of cancer that are dependent on EGF/EGFR, including many cases of prostate cancer.[10]
In Cuba, CimaVax-EGF has completed a
International
The United States embargo against Cuba forbids US citizens from seeking medical treatment in Cuba. However, some cancer patients from the US have defied the embargo and travelled to Cuba for treatment with CimaVax.[15]
Trials are being organized in the United States, the European Union, Japan,
In September 2018, Principal Investigator Grace Dy shared the initial results of the first Roswell Park trial.
The final results of this early trial were released in March 2019.[20] The results were in line with the September 2018 report, with the additional finding that patients receiving combination therapy in this trial were more likely to develop robust early antibody responses to CIMAvax as compared with what had been observed in earlier studies with CIMAvax alone.[20]
An ongoing
See also
References
- ^ a b "RESOLUCIÓN No. 2016006539 DE 25 de Febrero de 2016 Por la cual se concede un Registro Sanitario" (PDF). República de Colombia Ministerio de Salud y Protección Social Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA. Retrieved 28 December 2023.
- ^ S2CID 38130134.
- ^ Dillow C (8 September 2011). "Cuba Announces Release of the World's First Lung Cancer Vaccine". Popular Science. Retrieved 2011-12-11.
- ^ Grillo I (23 April 2015). "Cuba has had a lung cancer vaccine for years". GlobalPost. Retrieved 2014-05-24.
- ^ Wired. Retrieved 2015-05-13.
- ^ Tamayo H (8 September 2016). "Vacuna contra cáncer de pulmón llega al país". El Tiempo (Colombia). Retrieved 2016-09-09.
- ^ a b "Cuban anti-cancer vaccines soon to be available in Serbia". Tanjug. October 21, 2015.
- ISBN 978-0-300-23003-1.
- ^ "Can you tell me about the CimaVax lung cancer vaccine?". Cancer Research UK. 12 May 2015. Retrieved 2015-07-02.
- ^ PMID 20387330.
- S2CID 27200881.
- ^ PMID 18349395.
- PMID 22024351.
- PMID 28348561.
- ^ "Why an American went to Cuba for cancer care". BBC News. 19 April 2017. Retrieved 27 January 2023.
- ^ Davis H (26 October 2016). "Roswell Park gets go-ahead to test Cuban lung cancer vaccine". The Buffalo News. Retrieved 3 December 2016.
- ^ "CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-04-02.
- ^ Hoshaw L (2 December 2016). "Cuba Has a Lung Cancer Vaccine; Now U.S. Patients Will Test It". KQED News. Retrieved 3 December 2016.
- ^ a b c "Roswell Park Lung Cancer Expert Shares Initial Findings From First North American Study of CIMAvax". Roswell Park Comprehensive Cancer Center. September 26, 2018. Retrieved 10 April 2019.
- ^ a b c "With Safety Analysis Now Complete, Roswell Park Moves Forward With Expanded Study of CIMAvax". Roswell Park Comprehensive Cancer Center. March 30, 2019. Retrieved 10 April 2019.
- S2CID 259082182.